POTOMAC data support a year's worth of immuontherapy paired with BCG induction and maintenance
— POTOMAC data support a year's worth of immuontherapy paired with BCG induction and maintenance
by Mike Bassett, Staff Writer, MedPage Today
May 16, 2026
• 3 min read
WASHINGTON -- Add-on durvalumab (Imfinzi) reduced the number of early high-risk disease recurrences within the first year in patients with high-risk non-muscle-invasive bladder cancer (NMIBC), according to new analyses from the POTOMAC trial.
AstraZeneca scores with Imfinzi in another bladder cancer trial, rivaling Merck's Keytruda
AstraZeneca follows Merck with Phase 3 win in bladder cancer
Imfinzi set to become first immunotherapy for stomach cancer patients on NHS - Pharmaceutical Technology
Tecentriq lands FDA approval as adjuvant treatment for muscle invasive bladder cancer
Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod
Tumori, una nuova immunoterapia disponibile per tre neoplasie
